Cybin (HELP) Net Income towards Common Stockholders (2020 - 2024)
Cybin (HELP) posted Net Income towards Common Stockholders of -$0.02 for Q2 2024, up 69.75% on a QoQ basis from -$0.07 in Q4 2023, and up 61.62% year-over-year from -$0.01 in Q3 2023.
Cybin (HELP) Net Income towards Common Stockholders (2020 - 2024) Analysis & Trends
Cybin's Net Income towards Common Stockholders history runs 5 years deep, the most recent figure standing at -$0.02 for Q2 2024.
- Quarterly Net Income towards Common Stockholders rose 61.62% year-over-year to -$0.02 in Q2 2024, while the trailing twelve-month figure through Mar 2025 was -$0.02 (up 87.14% YoY) and the FY2026 annual result came in at -$147.8 million, down 74.01% from the prior year.
- Net Income towards Common Stockholders was -$0.02 for Q2 2024 at Cybin, up from -$0.07 in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $4.6 million in Q2 2022 and bottomed at -$0.1 in Q1 2022.
- A 5-year average of $303494.0 and a median of -$0.05 in 2023 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2021 — Net Income towards Common Stockholders plunged 191.12% — and 2024, when it jumped 61.62%.
- Cybin's Net Income towards Common Stockholders stood at -$0.08 in 2020, then declined by 3.43% to -$0.08 in 2021, then surged by 44.28% to -$0.04 in 2022, then sank by 49.56% to -$0.07 in 2023, then surged by 69.75% to -$0.02 in 2024.
- Business Quant data shows HELP's Net Income towards Common Stockholders at -$0.02 in Q2 2024, -$0.07 in Q4 2023, and -$0.04 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -0.68 |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 366.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Cybin | 262.76 Mn | 262.76 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -0.02 |
| Dec 31, 2023 | -0.07 |
| Sep 30, 2023 | -0.04 |
| Jun 30, 2023 | -0.05 |
| Dec 31, 2022 | -0.04 |
| Sep 30, 2022 | -0.05 |
| May 31, 2022 | 4.55 Mn |
| Mar 31, 2022 | -0.10 |
| Dec 31, 2021 | -0.08 |
| Sep 30, 2021 | -0.09 |
| Jun 30, 2021 | -0.07 |
| Mar 31, 2021 | -0.09 |
| Dec 31, 2020 | -0.08 |
| Sep 30, 2020 | -0.03 |
| Jun 30, 2020 | -0.05 |